Compare KOSS & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOSS | ATNM |
|---|---|---|
| Founded | 1953 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 36.8M |
| IPO Year | 1994 | 2013 |
| Metric | KOSS | ATNM |
|---|---|---|
| Price | $4.06 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 16.8K | ★ 115.6K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.00 | ★ 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,624,170.00 | $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $4.00 | $1.02 |
| 52 Week High | $8.59 | $1.95 |
| Indicator | KOSS | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 52.28 |
| Support Level | $4.07 | $1.02 |
| Resistance Level | $5.04 | $1.71 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 18.42 | 77.78 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.